Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company ...
Aura Biosciences, Inc. is a clinical-stage biotechnology company founded in 2009 and headquartered in Boston, Massachusetts. The company is dedicated to developing a new class of oncology targeted therapies that aim to provide meaningful therapeutic benefit across a range of cancer indications while preserving organ function. Aura leverages its proprietary ...Aura Biosciences, Inc. is a clinical-stage biotechnology company founded in 2009 and headquartered in Boston, Massachusetts. The company is dedicated to developing a new class of oncology targeted therapies that aim to provide meaningful therapeutic benefit across a range of cancer indications while preserving organ function. Aura leverages its proprietary virus-like drug conjugate (VDC) technology platform, which combines the specificity of viruses with the potency of cytotoxic drugs, to target tumors with high unmet medical needs, particularly in ocular and urologic oncology.
The company's flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma, a rare and serious eye cancer. Beyond that, Aura is exploring AU-011's potential for other ocular oncology applications, such as choroidal metastases. The company is also expanding its pipeline to address other solid tumors, with a strategic focus on indications where preserving organs is critical.
Financially, Aura is a pre-revenue company, with a market capitalization of approximately $826 million as of the latest data. The company has a working capital of $101.8 million and a current ratio of 7.09, indicating a strong short-term liquidity position. However, it operates with negative profitability metrics, as expected for a clinical-stage biotech, with a return on assets of -81.6% and a net income per share of -$1.67. Key financial ratios such as the price-to-book ratio (5.03) and the debt-to-equity ratio (0.158) suggest the company is financed primarily through equity.
In terms of leadership, the company was founded by Elisabet de los Pinos, Ph.D., who served as CEO until April 2026, when she stepped down. Natalie C. Holles, who brings over 25 years of executive leadership experience, succeeded her as CEO. The company employs 113 full-time staff and continues to advance its clinical programs, recently announcing a proposed public offering to fund its research and development. Aura's mission is to develop a new class of oncology therapies that deliver meaningful benefit while preserving organ function, positioning it as a potentially transformative player in precision cancer treatment.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-106.2M
-22.2%
-35.5%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-85.2M
-5.1%
-6.1%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
12.7%
+2.8%
-66.8%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
8.15x
-24.4%
+137.1%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
